Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
Viridian Therapeutics (NASDAQ: VRDN) has announced it will host a conference call and webcast on December 16, 2024, at 8:00 a.m. ET to present topline results from its THRIVE-2 Phase 3 clinical trial. The study evaluated the efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED). Investors can access the webcast through the company's website under 'Events and Presentations' or join via phone using the provided dial-in numbers.
Viridian Therapeutics (NASDAQ: VRDN) ha annunciato che ospiterà una conference call e un webcast il 16 dicembre 2024 alle 8:00 ET per presentare i risultati preliminari del suo studio clinico di fase 3 THRIVE-2. Lo studio ha valutato l'efficacia e la sicurezza di veligrotug in pazienti con malattia oculare tiroidea cronica (TED). Gli investitori possono accedere al webcast tramite il sito web dell'azienda nella sezione 'Eventi e Presentazioni' o partecipare telefonicamente utilizzando i numeri di accesso forniti.
Viridian Therapeutics (NASDAQ: VRDN) ha anunciado que llevará a cabo una conferencia telefónica y un webcast el 16 de diciembre de 2024 a las 8:00 a.m. ET para presentar los resultados preliminares de su ensayo clínico de fase 3 THRIVE-2. El estudio evaluó la eficacia y la seguridad de veligrotug en pacientes con enfermedad ocular tiroidea crónica (TED). Los inversores pueden acceder al webcast a través del sitio web de la empresa en la sección 'Eventos y Presentaciones' o unirse por teléfono utilizando los números de acceso proporcionados.
Viridian Therapeutics (NASDAQ: VRDN)는 2024년 12월 16일 오전 8시(동부 표준시)에 THRIVE-2 3상 임상 시험의 주요 결과를 발표하기 위해 컨퍼런스 콜 및 웹캐스트를 개최할 것이라고 발표했습니다. 이 연구는 만성 갑상선 안과 질환(TED) 환자에서 veligrotug의 효능과 안전성을 평가했습니다. 투자자들은 회사 웹사이트의 '이벤트 및 발표' 섹션을 통해 웹캐스트에 접속하거나 제공된 전화 접속 번호를 통해 참여할 수 있습니다.
Viridian Therapeutics (NASDAQ: VRDN) a annoncé qu'il organisera une conférence téléphonique et un webinaire le 16 décembre 2024 à 8h00 ET pour présenter les résultats préliminaires de son essai clinique de phase 3 THRIVE-2. L'étude a évalué l'efficacité et la sécurité de veligrotug chez des patients atteints de maladie chronique des yeux liée à la thyroïde (TED). Les investisseurs peuvent accéder au webinaire via le site Web de l'entreprise dans la section 'Événements et Présentations' ou participer par téléphone en utilisant les numéros d'appel fournis.
Viridian Therapeutics (NASDAQ: VRDN) hat bekannt gegeben, dass am 16. Dezember 2024 um 8:00 Uhr ET eine Telefonkonferenz und ein Webcast stattfinden werden, um die vorläufigen Ergebnisse seiner THRIVE-2 Phase-3-Studie zu präsentieren. Die Studie bewertete die Wirksamkeit und Sicherheit von veligrotug bei Patienten mit chronischer Schilddrüsenaugenkrankheit (TED). Investoren können auf den Webcast über die Unternehmenswebsite in der Rubrik 'Veranstaltungen und Präsentationen' zugreifen oder telefonisch über die bereitgestellten Einwahlnummern teilnehmen.
- Phase 3 clinical trial completion milestone reached
- Imminent release of topline results for key drug candidate
- None.
- THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) -
- Conference call and webcast to be held Monday, December 16, at 8:00 a.m. ET -
Conference call and webcast information
The webcast can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. To participate in the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference code 9934051. A replay of the webcast will be available following the completion of the event.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian is based in
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,” “project,” “design,” “should,” “target,” “will,” or “would” or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: preclinical and clinical development of Viridian’s product candidates veligrotug (formerly VRDN-001), VRDN-003, VRDN-006 and VRDN-008; Viridian’s product candidates potentially being best-in-class; and the potential for Viridian’s product candidates to be developed in multiple autoimmune diseases.
New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to the potential utility, efficacy, potency, safety, clinical benefits, clinical response and convenience of Viridian’s product candidates and those risks set forth under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 12, 2024 and other subsequent disclosure documents filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date hereof.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241213672239/en/
Anabel Chan, 617-458-8725
Vice President, Investor Relations & Communications
IR@viridiantherapeutics.com
Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
FAQ
When will Viridian Therapeutics (VRDN) release THRIVE-2 Phase 3 results?
What is the purpose of Viridian's THRIVE-2 Phase 3 trial?
How can investors access Viridian's THRIVE-2 results webcast?